Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Clinical News

Arvinas clears key hurdle, showing PROTACs orally bioavailable in clinic

October 23, 2019 9:23 PM UTC

Putting to rest concerns regarding oral bioavailability, Arvinas showed that its first two proteolysis-targeting chimeras achieved serum levels predicted to be efficacious.

Wednesday’s presentation of Phase I data of ARV-110 for metastatic castration-resistant prostate cancer (CRPC) and ARV-471 for ER-positive, HER2-negative breast cancer, represented the first clinical data reported by Arvinas Inc. (NASDAQ:ARVN). Arvinas shares rose $2.40 (15%) to $18.79 Wednesday...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article

BCIQ Company Profiles

Arvinas Inc.

BCIQ Target Profiles

Androgen receptor